Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

Stopped Insufficient funding

Conditions

• Acute Lymphoblastic Leukemia in Remission
• Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
• Chronic Myelomonocytic Leukemia
• Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
• Hematopoietic and Lymphoid System Neoplasm
• Myelodysplastic Syndrome
• Myelofibrosis
• Myeloproliferative Neoplasm
• Recurrent Acute Myeloid Leukemia
• Recurrent Hodgkin Lymphoma
• Recurrent Non-Hodgkin Lymphoma
• Refractory Acute Myeloid Leukemia
• Therapy-Related Acute Myeloid Leukemia

Interventions

• BIOLOGICAL: Anti-Thymocyte Globulin
• DRUG: Busulfan
• DRUG: Cyclophosphamide
• DRUG: Cyclosporine
• DRUG: Fludarabine Phosphate
• DRUG: Methotrexate
• PROCEDURE: Peripheral Blood Stem Cell Transplantation
• OTHER: Quality-of-Life Assessment
• OTHER: Questionnaire Administration
• DRUG: Tacrolimus
• RADIATION: Total-Body Irradiation

Sponsor

Fred Hutchinson Cancer Center